

Megabrand Voicemail
One Delivered by Lisa Lloyd Washington


Approximately November 14

This is Lisa Lloyd-Washington and I have some exciting news to share with you today. It's official! I am proud to report that as of today, SEROQUEL is officially a megabrand with over \$1 billion in year-to-date U.S. Product Sales. It's an impressive accomplishment, representing the first global megabrand for the CNS P&I TA. SEROQUEL now joins other AZ megabrands like [REDACTED] as pillars of growth that are seen as key drivers not only for their respective TAs but for AstraZeneca as a whole. I would like to express my sincerest appreciation to everyone that has worked so passionately to get us here today.

We know that moving forward we can build on our current momentum in the market place. In addition, we have exciting new opportunities on the short term horizon such as the mania indication. And, we continue to progress longer term clinical development such as the elderly program and new formulations.

We should all take a moment to be proud of this team accomplishment. Your contribution to achieving the success of SEROQUEL as a global megabrand is greatly appreciated. Your continued focussed efforts will drive this brand even beyond current expectations, so keep up the great work. Next stop is \$2 billion!!!

Thank you.



Megabrand Voicemail
One Delivered by Lisa Lloyd Washington

Approximately November 14

This is Lisa Lloyd-Washington and I have some exciting news to share with you today. It's official! I am proud to report that as of today, SEROQUEL is officially a megabrand with over \$1 billion in year-to-date U.S. Product Sales. It's an impressive accomplishment, representing the first global megabrand for the CNS P&I TA. SEROQUEL now joins other AZ megabrands like [REDACTED] as pillars of growth that are seen as key drivers not only for their respective TAs but for AstraZeneca as a whole. I would like to express my sincerest appreciation to everyone that has worked so passionately to get us here today.

We know that moving forward we can build on our current momentum in the market place. In addition, we have exciting new opportunities on the short term horizon such as the mania indication. And, we continue to progress longer term clinical development such as the elderly program and new formulations.

We should all take a moment to be proud of this team accomplishment. Your contribution to achieving the success of SEROQUEL as a global megabrand is greatly appreciated. Your continued focussed efforts will drive this brand even beyond current expectations, so keep up the great work. Next stop is \$2 billion!!!

Thank you.